RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation,...
Expects to launch and complete a Phase 1 trial in Q4 2023
A New Jersey-based %Biotech company is turning heads Tuesday morning after the company announced the signing an exclusive option agreement with %DanaFarberCancerInstitute to license technology targeting...
BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company...
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors...
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors...
Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent...
Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences...
Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review Novel...
R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments BRIDGEWATER,...